Cryoport Is Selected By Morphotek to Manage Cold Chain Logistics
Cryoport, Inc. the world’s leading cryogenic logistics company, and Morphotek® announced that Cryoport is providing end-to-end cold chain logistics support for shipments of Morphotek’s research and development materials.
Morphotek, a subsidiary of Eisai Inc., a global health care pharmaceutical company, is a life science company that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mAbs) being studied in diseases using its proprietary technology platforms:
- Human MORPHODOMA® technology employs an ex vivo immunization process in combination with morphogenics to generate fully human antibodies targeted against disease-associated antigens. The resultant antibodies are fully human with high-affinity and target specificity.
- Libradoma™ technology generates libraries of hybridomas that can be rapidly screened to identify fully human monoclonal antibodies to known antigens and novel targets for the diagnosis and treatment of diseases in humans. This platform is being widely pursued internally to feed Morphotek’s future therapeutic antibody pipeline.
Global Supply Chain Management Director of Morphotek, Mr. Myron Waskiw, stated, “By selecting Cryoport for our cold chain logistics, we are partnering with the most experienced cryogenic solutions provider. Cryoport understands the critical nature of our shipments, has the advanced capabilities to track conditions and location of our products in transit around the clock, and, importantly, has the intervention capability to mitigate any logistics risks. Cryoport’s solutions and capabilities are critical to the successful development of our therapeutic candidates.”
Mark Sawicki, PhD, Chief Commercial Officer of Cryoport, said, “Cryoport is thrilled to have been selected by Morphotek to manage the cold chain logistics supporting research for its biological-based programs to treat cancer, inflammation and infectious diseases. This relationship further solidifies our position as the leading provider of complete cold chain solutions for innovative therapeutics.”
Cryoport is currently supporting 52 clinical trials for advanced therapies and regenerative medicines, including 10 in Phase III, for biopharmaceutical companies around the world.